Q32 Bio’s bempikibart shows signs of a remittive effect in alopecia areata—Here’s what that means
Q32 Bio Inc. has released promising SIGNAL-AA trial results, shedding new light on the potential of bempikibart clinical data as an innovative alopecia areata treatment. ... Read More
Longeveron 2024 revenue jumps 237%, eyes FDA approval for Lomecel-B
Longeveron Inc., a biotechnology company specializing in regenerative medicine, has reported significant financial progress alongside major advancements in its investigational stem cell therapy, Lomecel-B. The ... Read More
4D Molecular Therapeutics strengthens cash position, eyes Phase 3 success for 4D-150
4D Molecular Therapeutics (4DMT) has announced its full-year 2024 financial results, highlighting key advancements in its late-stage clinical pipeline. With a primary focus on its ... Read More
Praxis Precision Medicines faces major setback in ulixacaltamide trial but remains committed to Essential3 study
Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company specializing in treatments for central nervous system disorders, encountered a significant challenge as an independent data ... Read More
Recce Pharmaceuticals advances R327 Gel towards Phase 3 after promising Phase II trial
Recce Pharmaceuticals Limited has announced significant success in its Phase II trial of RECCE 327 topical gel (R327G), a synthetic anti-infective designed to treat acute ... Read More
Wockhardt’s Zaynich achieves record-breaking 96.8% clinical cure rate in cUTI Phase III trial
Wockhardt Limited has announced a major breakthrough in the treatment of complicated urinary tract infections (cUTI) with its novel antibiotic Zaynich (Zidebactam/Cefepime, WCK 5222). In ... Read More
CliniOps and Indegene partner to redefine clinical trial efficiency with digital innovation
CliniOps, a leading innovator in advanced digital clinical trial solutions, has entered into a strategic partnership with Indegene, a digital-first life sciences commercialization company. This ... Read More
Swiss biotech company Noema Pharma secures CHF130m to advance CNS therapies
Basel, Switzerland-based Noema Pharma, a clinical-stage biotech company, has announced the successful close of its Series B financing round extension, securing CHF 130 million (approximately ... Read More
Merck’s WELIREG receives positive CHMP opinion for VHL tumours and advanced RCC
Merck, known as MSD outside the U.S. and Canada, has moved a step closer to offering innovative treatment options in Europe. The European Medicines Agency’s ... Read More
Actinogen Medical progresses in XanaMIA Phase 2b/3 trial for Alzheimer’s disease
Actinogen Medical Limited (ASX: ACW) has announced a major milestone in its ongoing XanaMIA Phase 2b/3 clinical trial, aimed at treating biomarker-positive mild to moderate ... Read More